ArticleStem cell research & therapy2019
Labeling of human mesenchymal stem cells with different classes of vital stains: robustness and toxicity.
Article in Stem cell research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Mesenchymal stem cells as cellular factories for targeted P2X7 blockade after traumatic brain injury.Neuroprotection (Chichester, England) · 2026Article
- A new flow chip in combination with multiphoton microscopy as a protocol for longitudinal 3D imaging of tissue calcification under shear stress.FEBS open bio · 2026Article
- The favorable role of recombinant collagen peptide in periosteal cell-derived osteoregeneration.Regenerative therapy · 2026Article
- Dynamic, single-cell monitoring of CAR T cell identity and activation with Raman spectroscopy.bioRxiv : the preprint server for biology · 2026Article
- No simple way to averaging out: Pooled mesenchymal stromal cells do not reflect average donor characteristics.Regenerative therapy · 2025Article
- Biodistribution and persistence of human umbilical cord-derived mesenchymal stem cells in NCG mice: a comparative study.Future science OA · 2025Article
- Article
- Dielectrophoretic Microfluidic Designs for Precision Cell Enrichments and Highly Viable Label-Free Bacteria Recovery from Blood.Micromachines · 2025Article
- Smart CAR-T Nanosymbionts: archetypes and proto-models.Frontiers in immunology · 2025Review
- Tracking of autologous adipose-derived mesenchymal stromal/stem cells after intravenous administration: a pilot study in a dog with induced acute bladder injury.Frontiers in veterinary science · 2025Article
- Label-free ghost cytometry for manufacturing of cell therapy products.Scientific reports · 2024Article
- Fluorescence-Based Mono- and Multimodal Imaging for In Vivo Tracking of Mesenchymal Stem Cells.Biomolecules · 2023Review
- Virtual staining for pixel-wise and quantitative analysis of single cell images.Scientific reports · 2023Article
- Mesenchymal stem cell engineering by ARCA analog-capped mRNA.Molecular therapy. Nucleic acids · 2023Article
- Article
- Dynamic MRI of the Mesenchymal Stem Cells Distribution during Intravenous Transplantation in a Rat Model of Ischemic Stroke.Life (Basel, Switzerland) · 2023Article
- Cobalt Ferrite Magnetic Nanoparticles for Tracing Mesenchymal Stem Cells in Tissue: A Preliminary Study.International journal of molecular sciences · 2022Article
- Prodigious therapeutic effects of combining mesenchymal stem cells with magnetic nanoparticles.World journal of stem cells · 2022Review
- Standard toxicity study of clinical-grade allogeneic human bone marrow-derived clonal mesenchymal stromal cells.Stem cell research & therapy · 2022Article
- Mesenchymal Stem Cells Do Not Lose Direct Labels Including Iron Oxide Nanoparticles and DFO-Membranes · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesenchymal stem cell (MSC) transplantation has been explored as a new clinical approach to repair injured tissues. However, in order to evaluate the therapeutic activity of MSC, cell tracking techniques are required to determine the fate of transplanted cells in both preclinical and clinical studies. In these aspects, different vital stains offer the potential for labeling and monitoring of grafted cells in vivo. It is desirable to have tracking agents which have long-term stability, are not toxic to the cells, and do not affect cell function.
methodsHere, we selected three different labels: CellTracker™ Green CMFDA, eGFP-mRNA (genetic pre-tag), and Molday ION Rhodamine B™ (nanoparticle-based fluorescent and magnetic label) and performed extensive analysis of their influence on in vitro expansion of human bone marrow-derived mesenchymal stem cells (hBM-MSCs), as well as potential of affecting therapeutic activity and the impact on the durability of staining.
resultsOur study showed that basic hBM-MSC characteristics and functions might be affected by labeling. We observed strong alterations of metabolic activity and morphology after eGFP and CellTracker™ Green CMFDA hBM-MSC staining. Molday ION Rhodamine B™ labeling revealed superior properties relatively to other vital stains. The relative expression level of most of the investigated growth factors remained stable after cell labeling, but we have observed some changes in the case of EGF, GDNF, HGF, and IGF gene expression.
conclusionsTaken together, we suggest performing similar to ours extensive analysis prior to using any cell label to tag MSC in experiments, as it can thoroughly bias results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.